NASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis $73.54 +1.12 (+1.55%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$73.02▼$76.1250-Day Range$67.99▼$80.8452-Week Range$45.50▼$84.89Volume840,108 shsAverage Volume945,298 shsMarket Capitalization$7.76 billionP/E RatioN/ADividend YieldN/APrice Target$96.58 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Intra-Cellular Therapies alerts: Email Address Intra-Cellular Therapies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside31.3% Upside$96.58 Price TargetShort InterestHealthy2.41% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.94Based on 10 Articles This WeekInsider TradingSelling Shares$14.89 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.59) to $0.53 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.68 out of 5 starsMedical Sector57th out of 910 stocksPharmaceutical Preparations Industry21st out of 426 stocks 4.4 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageIntra-Cellular Therapies has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intra-Cellular Therapies' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.41% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intra-Cellular Therapies has recently increased by 2.01%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 2.7 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Intra-Cellular Therapies this week, compared to 5 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,892,738.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intra-Cellular Therapies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.59) to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -63.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -63.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 6.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Intra-Cellular Therapies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Intra-Cellular Therapies Stock (NASDAQ:ITCI)Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Stock News HeadlinesAugust 31, 2024 | insidertrades.comInsider Selling: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sells 34,396 Shares of StockAugust 29, 2024 | insidertrades.comInsider Selling: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sells 40,513 Shares of StockSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 28, 2024 | insidertrades.comSharon Mates Sells 28,680 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) StockAugust 21, 2024 | insidertrades.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Sells $1,405,047.12 in StockSeptember 7 at 2:42 PM | msn.comPiper Sandler Upgrades Intra-Cellular Therapies (ITCI)September 5 at 4:01 AM | insidermonkey.comIntra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy NowSeptember 1, 2024 | americanbankingnews.comSharon Mates Sells 34,396 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) StockSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 29, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 40,513 Shares of StockAugust 28, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sells $4,010,433.45 in StockAugust 28, 2024 | globenewswire.comIntra-Cellular Therapies to Present at Three Upcoming Investor ConferencesAugust 9, 2024 | markets.businessinsider.comMorgan Stanley Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)August 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Intra-Cellular Therapies Amid Strong Sales and Expansion PotentialAugust 8, 2024 | investors.comBiotech Stock Pulls Back After Earnings Report; Profits On The HorizonAugust 8, 2024 | seekingalpha.comIntra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | globenewswire.comIntra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth ConferenceAugust 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Intra-Cellular Therapies Amidst Strong Q2 Sales and Strategic Growth InitiativesSee More Headlines Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees560Year FoundedN/APrice Target and Rating Average Stock Price Target$96.58 High Stock Price Target$130.00 Low Stock Price Target$74.00 Potential Upside/Downside+31.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,670,000.00 Net Margins-14.93% Pretax Margin-14.77% Return on Equity-11.48% Return on Assets-9.60% Debt Debt-to-Equity RatioN/A Current Ratio7.81 Quick Ratio7.69 Sales & Book Value Annual Sales$563.44 million Price / Sales13.78 Cash FlowN/A Price / Cash FlowN/A Book Value$10.83 per share Price / Book6.79Miscellaneous Outstanding Shares105,575,000Free Float101,985,000Market Cap$7.76 billion OptionableOptionable Beta1.01 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Sharon Mates Ph.D. (Age 71)Co-Founder, Chairman & CEO Comp: $2.23MMr. Michael I. Halstead J.D. (Age 51)President Comp: $983.65kDr. Suresh K. Durgam M.D. (Age 55)Executive VP & Chief Medical Officer Comp: $961.84kMr. Mark Neumann (Age 61)EVP & Chief Commercial Officer Comp: $998.36kDr. Robert E. Davis Ph.D. (Age 73)Senior VP & Chief Scientific Officer Comp: $646.12kMr. Juan Fernando Sanchez (Age 53)Vice President of Corporate Communications & Investor Relations Comp: $296.75kMs. Karen Patruno Sheehy Esq. (Age 62)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsDr. Willie R. Earley M.D.Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsViela BioNASDAQ:VIERa PharmaceuticalsNASDAQ:RARXAimmune TherapeuticsNASDAQ:AIMTKura OncologyNASDAQ:KURAZymeworksNYSE:ZYMEView All CompetitorsInsiders & InstitutionsGhisallo Capital Management LLCBought 50,000 shares on 9/4/2024Ownership: 0.047%Sharon MatesSold 34,396 sharesTotal: $2.51 M ($72.84/share)Clearbridge Investments LLCSold 22,941 shares on 8/27/2024Ownership: 1.631%Sharon MatesSold 40,513 sharesTotal: $2.98 M ($73.58/share)Sharon MatesSold 28,680 sharesTotal: $2.14 M ($74.46/share)View All Insider TransactionsView All Institutional Transactions ITCI Stock Analysis - Frequently Asked Questions How have ITCI shares performed this year? Intra-Cellular Therapies' stock was trading at $71.62 on January 1st, 2024. Since then, ITCI stock has increased by 2.7% and is now trading at $73.54. View the best growth stocks for 2024 here. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.03. The business's revenue for the quarter was up 45.7% on a year-over-year basis. Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' top institutional shareholders include Avoro Capital Advisors LLC (2.84%), Clearbridge Investments LLC (1.63%), Perceptive Advisors LLC (1.63%) and Millennium Management LLC (0.84%). Insiders that own company stock include Sharon Mates, Rory B Riggs, Joel S Marcus, Mark Neumann, Michael Halstead, Suresh K Durgam, Nostrand Robert L Van and Lawrence J Hineline. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV) and Novavax (NVAX). This page (NASDAQ:ITCI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITCI Stock Alerts